399 — Innovative Pharmaceutical Biotech Income Statement
0.000.00%
- HK$387.72m
- HK$2.32bn
- HK$8.08m
- 16
- 41
- 20
- 11
Annual income statement for Innovative Pharmaceutical Biotech, fiscal year end - March 31st, HKD millions except per share, conversion factor applied.
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 18.6 | 14.6 | 15.2 | 11.1 | 8.07 |
Cost of Revenue | |||||
Gross Profit | 1.75 | 1.62 | 1.41 | 1.05 | 0.858 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 161 | 96.3 | 36.3 | -215 | 28.8 |
Operating Profit | -143 | -81.7 | -21.1 | 226 | -20.7 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -261 | -222 | -212 | 36.4 | -255 |
Provision for Income Taxes | |||||
Net Income After Taxes | -261 | -222 | -212 | 36.4 | -255 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -260 | -211 | -205 | 45.8 | -246 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -260 | -211 | -205 | 45.8 | -246 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.16 | -0.126 | -0.14 | -0.14 | -0.168 |